Dyno Therapeutics, a leading company in AI-driven AAV capsid design, will showcase its latest research on enhancing gene delivery for genetic medicine at the upcoming ASGCT and SynBioBeta conferences, highlighting the potential and challenges of using AI in gene therapy.
Dyno Therapeutics to Discuss Advances in AI-Driven AAV Capsid Design at Major Scientific Conferences
April 23, 2024
WATERTOWN, Mass.—Dyno Therapeutics, a company at the forefront of integrating artificial intelligence (AI) for adeno-associated virus (AAV) capsid design, is set to present its latest research at the 27th Annual Congress of the American Society of Gene & Cell Therapy (ASGCT) and the SynBioBeta Global Synthetic Biology Conference. These events are scheduled for early May 2024 in Baltimore, Maryland, and San Jose, California, respectively.
Founded in 2018, Dyno Therapeutics has established itself as a leader in the application of AI to enhance gene delivery for genetic medicine. The company’s platform leverages AI to create optimized AAV capsids, expanding the potential to target various tissues such as the eye, muscle, and brain.
During the ASGCT conference, taking place from May 7 to 11, Dyno will host a Scientific Symposium and present three research abstracts, including one oral presentation. At the SynBioBeta conference from May 6 to 9, the company will focus on the implications of machine learning (ML) in synthetic biology.
Dyno’s presentations are expected to underscore the progress and challenges in using AI for gene therapy. The company asserts that their AI-driven approaches have led to significant improvements in gene delivery vectors, which may widen the therapeutic options available for genetic diseases.
At ASGCT, Dyno’s Scientific Symposium, titled “AAV Capsid Design in the Era of Artificial Intelligence”, will be presented by the company’s Founder and CEO, Eric Kelsic, Ph.D., on May 9, from 12:15 to 13:15 EDT. The session will highlight how AI can design novel capsids that are tailored for multiple in vivo delivery properties, potentially increasing the number of patients who could benefit from gene therapies.
The oral presentation, “Applying Artificial Intelligence to Multi-Property Optimization of AAV Capsids for Neuronal Gene Delivery,” is slated for May 10, from 17:00 to 17:15 EDT at the Baltimore Convention Center. This presentation will discuss the application of AI in optimizing AAV capsids specifically for neuronal gene delivery.
Additionally, Dyno will present two posters: “Non-Human Primate Evaluation of an Engineered AAV Capsid for Retinal Cell-Specific and Biofactory-Based Ocular Gene Therapies” on May 8, from 12:00 to 19:00 EDT, and “Expanding the Serotype Frontier: Design of Synthetic AAV Capsids with Artificial Intelligence” on May 10, from 12:00 to 19:00 EDT.
At SynBioBeta, Dyno’s presentations include an oral session titled “AI-Designed Capsids: Powering a New Age of Genetic Medicine,” on May 8, from 11:00 to 11:45 PDT, and a “Lunch & Learn” session, “Generative AI is Not Enough: Bridging In-Silico to Impact—Where Hype Faces Reality,” on May 9, from 12:15 to 13:00 PDT. These sessions will tackle the practicalities and hurdles of deploying ML in real-world applications for gene therapy.
Dyno Therapeutics collaborates with numerous gene therapy developers, including notable partnerships with Astellas, Novartis, Roche, and Sarepta. The company maintains an open stance for further collaborations across various therapeutic areas, aiming to broaden the range of diseases treatable with their AI-designed gene delivery systems.
For more information on Dyno Therapeutics, visit www.dynotx.com.
